Cannabinoid - Isolate, Distillate, oil and formulated hemp's products

Main non-psychoactive cannabinoid extracted from hemp, the cannabidiol or CBD molecule (identified in 1963) is derived from Cannabis sativa which contains more than 100 chemical compounds (mainly Cannabidiol [CBD], Cannabinol [CBN], Cannabichromene [CBC], Cannabigerol [CBG]). Also, CBD is rapidly becoming the focus of many uses in the pharmaceutical, cosmetic and of course dietary supplement fields.
Cannabidiol has no reported psychoactive effect (different receptors in the brain). Studies show that it seems to modulate the action of endocannabinoids naturally produced by the brain (regulation of the concentration of anandamide: the amount of anandamide increases, which promotes the innate endocannabinoid response of the body) but also directly on other important biological pathways.
Its action on the endocannabinoid system leads to various properties: digestion, metabolism, memory, regulation of stress and emotions... and thus plays a key role in the proper functioning of the human body.
Why GVB Biopharma?
GVB Biopharma is a leading and trusted historical supplier. Vertical integration is a key operational strategy at GVB Biopharma! It starts with the quality control of the seed from a selection of seeds, cultivation areas, and continues at each stage of processing and development. And this integration allows an optimal traceability, as well as the compilation of all the tests carried out continuously throughout the production process. The warehouse located in Europe also allows for the quick delivery of our isolates, distillates, crude oil and products formulated in partnership with other entities of the 22nd Century group. GVB is certified GMP, non-GMO, organic [CCOF and USDA], etc..
Processed by GVB, the extracts come from certified seeds and grown in referenced areas, and are analyzed both internally and by independent ORELAP accredited laboratories.
European regulation
The use of Hemp (Cannabis sativa) in food supplements varies in Europe. All countries consider a limit on the THC content (0.2% generally). Although Cannabinoids are not authorized in FS (at of today), member states are nevertheless trying to adapt to the growing evolution of this market, and a number of applications for authorization are underway. Thus, the French authorities have authorized the registration of products including less than 50mg of CBD, even if this registration does not mean authorization.